-
-
XIAOJUN HUANG
- Emailxjhrm@medmail.com.cn
- Phone+86-10-88326006
- Department
- Research Interest
- Homepage
Main Publications:1. Huang XJ*, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH, Jiang B, Jiang Q, Jiang H, Chen YH, Chen H, Han W, Liu KY, Wang Y, The superiority of haploidentical related stem cell transp
Main Publications:
1. Huang XJ*, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH, Jiang B, Jiang Q, Jiang H, Chen YH, Chen H, Han W, Liu KY, Wang Y, The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-or high-risk acute myeloid leukemia in first complete remission. BLOOD, 119(23): 5584-90, 2012.
2. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ*. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. BLOOD, 119(14): 3256-62, 2012.
3. Yu Wang, Dai-Hong Liu, Kai-Yan Liu, Lan-Ping Xu, Xiao-Hui Zhang, Wei Han, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Jing-Zhi Wang, Yu-Qian Sun, Xiao-Jun Huang*, Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in-vitro T-cell-depletion for the treatment of leukemia: nine years of experience at a single center. CANCER, CNCR-12-0995.R1, 2012. (In Press)
4. Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang H, Chen H, Chen YH, Han W, Zhang XH, Wang Y, Qin YZ, Liu YR, Lai YY, Huang XJ*. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood. 2011 Mar 17;117(11):3032-40.
5. Zhao XY, Xu LL, Lu SY, Huang XJ*, IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation. Eur J Immunol, 41(2): 514-26, 2011.
6. Liu K, Chen Y, Zeng Y, Xu L, Liu D, Chen H, Zhang X, Han W, Wang Y, Zhao T, Wang J, Wang J, Han Q, Zhao C, Huang XJ*, Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study. STEM CELL, 20(10): 1679-85, 2011.
7. Sun YQ, Xu LP, Liu DH, Zhang XH, Chen YH, Chen H, Ji Y, Wang Y, Han W, Wang JZ, Wang FR, Liu KY, Huang XJ*. The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion. CLIN MICROBIOL INFECT, doi: 10.1111/j.1469-0691.03697.x, 2011. (In Press)
8. Xiao-Jun H*, Lan-Ping X, Kai-Yan L, Dai-Hong L, Yu W, Huan C, Yu-Hong C, Wei H, Jing-Zhi W, Yao C, Xiao-Hui Z, Hong-Xia S, Feng-Rong W, Fei-Fei T, Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. CLINICAL CANCER RESEARCH, 15(14): 4777-83, 2009.
9. Huang XJ*, Zhao XY, Liu DH, Liu KY, Xu LP, Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. LEUKEMIA, 21(4): 848-51, 2007.
10. Huang XJ*, Liu DH, Liu KY, Xu LP, Chen H, Han W, Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. HAEMATOLOGCIA, 92(3): 414-7, 2007.